Safety and Phosphate-Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers.

ABSTRACT: Despite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end-stage kidney disease on dialysis. Characteristics of currently available phosphate binders that lead to poor patient experiences such as large drug volume size of required daily medication (e.g., many large tablets) and adverse gastrointestinal effects may decrease compliance to labeled dosing instructions, thus decreasing their efficacy. Oxylanthanum carbonate is a new molecule yielding the same phosphate-binding capacity as lanthanum carbonate, but in a much smaller drug volume and tablet size. It is formulated as small tablets that can be easily swallowed. In a double-blind dose-escalation phase 1 study, healthy volunteers (n = 32) were randomly d

SUBMITTER: Pergola PE 

PROVIDER: S-EPMC11672196 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature